SCHEMBL12008419

SCHEMBL12008419

COc1ccc(/C=C2\SC(=S)N(CCCC(=O)Nc3ccccc3C(=O)O)C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 12/20 1.00
▸ MEN1 O00255 10/20 1.00
▸ TNNI3 P19429 1/20 0.81
▸ TNNT2 P45379 1/20 0.81
▸ TNNC1 P63316 1/20 0.81
▸ POLB P06746 4/20 0.80
▸ RAB9A P51151 2/20 0.76
▸ CTDSP1 Q9GZU7 2/20 0.76
▸ BLM P54132 1/20 0.76
▸ MAPT P10636 7/20 0.73
▸ SMN1; SMN2 Q16637 2/20 0.73
▸ ALDH1A1 P00352 1/20 0.73
▸ LMNA P02545 1/20 0.73
▸ PLA2G1B P04054 1/20 0.73
▸ GFER P55789 1/20 0.73
▸ ATG4B Q9Y4P1 1/20 0.73
▸ MITF O75030 2/20 0.73
▸ NPC1 O15118 2/20 0.73
▸ MAPK1 P28482 2/20 0.72
▸ DDX3X O00571 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11918202 0.95 KMT2A (1.00) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008578 0.92 KMT2A (0.84) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008763 0.91 KMT2A (0.88) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008616 0.91 KMT2A (0.83) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008786 0.90 KMT2A (1.00) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008613 0.90 TNNI3 (1.00) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008775 0.89 POLB (1.00) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008601 0.89 KMT2A (0.83) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL12008753 0.86 KMT2A (1.00) KMT2AMEN1TNNI3TNNT2TNNC1
SCHEMBL18539144 0.86 KMT2A (0.83) KMT2AMEN1TNNI3TNNT2TNNC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 KMT2A 4503/4885MEN1 3747/4885TNNI3 3243/4885
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof CTNNB1, CTNNA1, CTNNBL1 KMT2A 4591/4885MEN1 4655/4885TNNI3 2840/4885
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 KMT2A 4591/4885MEN1 4655/4885TNNI3 2840/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 KMT2A 4591/4885MEN1 4655/4885TNNI3 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback